crizotinib + sunitinib

Crizotinib + sunitinib is a combination of two small-molecule tyrosine kinase inhibitors used primarily in oncology research. Crizotinib targets anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), and MET proto-oncogene receptor tyrosine kinase (MET), inhibiting their activity to block tumor cell proliferation and survival. It is approved for ALK- or ROS1-positive non-small cell lung cancer (NSCLC), as well as ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumor[4]. Sunitinib inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor alpha, platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor (VEGFR), KIT proto-oncogene receptor tyrosine kinase (KIT) (CD117), RET proto-oncogene receptor tyrosine kinase (RET), colony stimulating factor 1 receptor (CSF-1R), and FLT3 proto-oncogene (FLT3). This broad inhibition disrupts tumor angiogenesis and proliferation; it is approved for renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors[5][6]. Both drugs are associated with hepatotoxicity mediated by mitochondrial oxidative stress when used individually or together[1][3].